1. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment

2. Introduction

3. BP Classification: JNC7 vs 2017 ACC/AHA HTN Guidelines

4. BP Thresholds and Therapy Goals in Patients With HTN According to Clinical Conditions

5. Prevalence of HTN in the US According to JNC7 and 2017 ACC/AHA Guidelines

6. Potential Challenges With Labeling a Healthy Person as Hypertensive

7. 2017 ACC/AHA Guidelines and the Older Adult

8. BP Management and CV Risk in Older Adults

9. Results From SPRINT

10. Considerations Regarding Results of the SPRINT Study

11. 2017 ACC/AHA Recommendations for BP Treatment in the Context of CVD Risk

12. 2017 ACC/AHA Recommendations for BP Treatment in the Context of CVD Risk (cont)

13. 2017 ACC/AHA Recommendations for Use of Nonpharmacological Therapy

14. Concerns Regarding 2017 ACC/AHA Recommendations for Nonpharmacological Therapy

15. An Alternate Approach to Starting Nonpharmacological Therapy

16. Concerns Regarding 2017 ACC/AHA Recommendations for Nonpharmacological Therapy (cont)

17. European Response to New US Guidelines

18. BP Reduction and the Role of FDC Therapy

19. Adherence to Antihypertensive Treatment and BP Changes in Initially Nonadherent Patients in the UK

20. Combination Therapy Increases BP-Lowering Much More Effectively Than Monotherapy

21. Selection of Antihypertensive Drug Combinations

22. FDC Therapy: A Practical Necessity

23. Summary

24. Summary (cont)

25. Abbreviations

26. Abbreviations (cont)